donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

GBT Global Blood Therapeutics

67.020
-0.030-0.04%
Close 08/19 16:00 ET
67.02000.00%
Post Mkt Price 08/19 16:00 ET
High
67.200
Open
67.100
Turnover
317.72M
Low
66.910
Pre Close
67.050
Volume
4.74M
Market Cap
4.52B
P/E(TTM)
Loss
52wk High
73.020
Shares
67.46M
P/E(Static)
Loss
52wk Low
21.650
Float Cap
3.92B
Bid/Ask %
-71.43%
Historical High
87.540
Shs Float
58.44M
Volume Ratio
0.98
Historical Low
12.240
Dividend TTM
--
Div Yield TTM
250
P/B
38.21
Dividend LFY
--
Div Yield LFY
373.02%
Turnover Ratio
8.11%
Amplitude
0.43%
Avg Price
67.008
Lot Size
1
Float Cap
3.92B
Bid/Ask %
-71.43%
Historical High
87.540
Shs Float
58.44M
Volume Ratio
0.98
Historical Low
12.240
Dividend TTM
--
P/B
38.21
Dividend LFY
--
Turnover Ratio
8.11%
Amplitude
0.43%
Avg Price
67.008
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
CEO: Love M.D., Ted W.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...